Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Br J Haematol. 2022 Nov;199(3):366-370. doi: 10.1111/bjh.18383. Epub 2022 Jul 27.
Outcomes remain poor for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). While chimeric antigen receptor (CAR) T-cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 × CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R/R B-NHL in a first-in-human trial (NCT02290951). Here, we document two patients with diffuse large B-cell lymphoma refractory to CART-cell therapy. Both achieved complete responses that remain ongoing for ≥2 years following odronextamab. Neither patient experienced Grade ≥3 cytokine release syndrome or Grade ≥3 neurological adverse events during treatment.
复发/难治性 B 细胞非霍奇金淋巴瘤 (R/R B-NHL) 患者的预后仍然较差。嵌合抗原受体 (CAR) T 细胞疗法的出现彻底改变了治疗方法，但仍有相当一部分患者复发或无应答。在一项首次人体试验 (NCT02290951) 中，Odronextamab 是一种 CD20×CD3 双特异性抗体，在 R/R B-NHL 患者中显示出持久的应答和可管理的安全性。在这里，我们记录了两名对 CART 细胞治疗难治的弥漫性大 B 细胞淋巴瘤患者。两名患者均在接受 odronextamab 治疗后 2 年以上持续完全缓解。在治疗过程中，两名患者均未出现≥3 级细胞因子释放综合征或≥3 级神经毒性不良反应。
